# TOP (NCT04695925)

> Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04695925
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Li Zhang, MD
- Conditions: Non-small Cell Carcinoma; EGFR Gene Mutation
- Interventions: Osimertinib; Pemetrexed; Carboplatin
- Enrollment: 294
- Primary outcome: progression free survival

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=top-nct04695925